Ligand Pharmaceuticals Inc (LGND): Jason Aryeh , director of Ligand Pharmaceuticals Inc sold 25,000 shares on May 5, 2016. The Insider selling transaction was reported by the company on May 9, 2016 to the Securities and Exchange Commission. The shares were sold at $119.37 per share for a total value of $2,979,954.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 3, 2016, John W Kozarich (director) sold 1,000 shares at $121.75 per share price.On Mar 17, 2016, Matthew W Foehr (President and COO) sold 6,400 shares at $96.70 per share price.Also, On Mar 9, 2016, John L Higgins (Chief Executive Officer) sold 10,833 shares at $102.71 per share price.On Mar 9, 2016, Jason Aryeh (director) sold 6,129 shares at $101.78 per share price.
Ligand Pharmaceuticals: On Friday, May 6, 2016 heightened volatility was witnessed in Ligand Pharmaceuticals which led to swings in the share price. The shares opened for trading at $117.41 and hit $119.23 on the upside , eventually ending the session at $119.17, with a gain of 0.79% or 0.93 points. The heightened volatility saw the trading volume jump to 4,00,094 shares. The 52-week high of the share price is $131.84 and the company has a market cap of $2,476 M . The 52-week low of the share price is at $71.63.
Company has been under the radar of several Street Analysts.Ligand Pharmaceuticals is Initiated by Sidoti to Buy. The Rating was issued on Mar 11, 2016.Ligand Pharmaceuticals is Initiated by H.C. Wainwright to Buy and the brokerage firm has set the Price Target at $146. The Rating was issued on Mar 3, 2016.
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company’s technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases such as hepatitis multiple myeloma muscle wasting Alzheimers disease dyslipidemia diabetes anemia epilepsy focal segmental glomerulosclerosis (FSGS) and osteoporosis.